Güven, Deniz CanŞahin, Taha KorayErul, EnesÇakır, İbrahim YahyaÜçgül, EnesYıldırım, Hasan ÇağrıAktepe, Oktay HalitErman, MustafaKılıçkap, SaadettinAksoy, SercanYalçın, Suayib2022-08-172022-08-172022Guven DC, Sahin TK, Erul E, Cakir IY, Ucgul E, Yildirim HC, Aktepe OH, Erman M, Kilickap S, Aksoy S, Yalcin S. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. J Clin Med. 2022 Aug 3;11(15):4523. doi: 10.3390/jcm11154523. PMID: 35956139; PMCID: PMC9369683.2077-0383http://doi.org/10.3390/jcm11154523https://hdl.handle.net/20.500.12713/3100Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the neutrophil-lymphocyte ratio (NLR) and early NLR changes with survival in ICI-treated patients. We retrospectively evaluated the data of 231 patients with advanced-stage cancer. We recorded baseline clinical characteristics, baseline NLR and fourth-week NLR changes, and survival data. A compound prognostic score, the NLR2-CEL score, was developed with the following parameters: baseline NLR (<5 vs. ?5), ECOG status (0 vs. ?1), Charlson Comorbidity Index (CCI, <9 vs. ?9), LDH (N vs. ?ULN), and fourth-week NLR change (10% or over NLR increase). In the multivariable analyses, higher NLR (HR: 1.743, p = 0.002), 10% or over NLR increase in the fourth week of treatment (HR: 1.807, p = 0.001), higher ECOG performance score (HR: 1.552, p = 0.006), higher LDH levels (HR: 1.454, p = 0.017), and higher CCI (HR: 1.400, p = 0.041) were associated with decreased OS. Compared to patients with the lowest scores, patients in the highest score group had significantly lower OS (HR: 7.967, 95% CI: 3.531-17.979, p < 0.001) and PFS. The composite score had moderate success for survival prediction, with an AUC of 0.702 (95% CI: 0.626-0.779, p < 0.001). We observed significantly lower survival in patients with higher baseline NLR values and increased NLR values under treatment.eninfo:eu-repo/semantics/openAccessCharlson Comorbidity IndexNLR2-CELBiomarkerCancerImmunotherapyNeutrophillymphocyte RatioArticle11159369683WOS:0008391333000012-s2.0-85136967089Q210.3390/jcm11154523Q1